Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma

doi:10.3748/wjg.v28.i36.5250

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 36

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8532)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

432

WORD

HTML

4416

Figures (1-2)

658

Tables (1-3)

722

Sum=6322

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

640

Download

1581

Sum=2221

Sep 28, 2022 (publication date) through Mar 5, 2026

Times Cited of This Article

Times Cited (29)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastroenterol. Sep 28, 2022; 28(36): 5250-5264
Published online Sep 28, 2022. doi: 10.3748/wjg.v28.i36.5250

Deciphering the role of transforming growth factor-beta 1 as a diagnostic-prognostic-therapeutic candidate against hepatocellular carcinoma

Aswathy R Devan, Keechilat Pavithran, Bhagyalakshmi Nair, Maneesha Murali, Lekshmi R Nath

Aswathy R Devan, Bhagyalakshmi Nair, Maneesha Murali, Lekshmi R Nath, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, Kerala, India

Keechilat Pavithran, Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi 682041, Kerala, India

Author contributions: Nath LR conceptualized, designed the review content and revised the draft; Devan AR wrote the draft; Pavithran K revised and proofread; Nair B and Murali M collected the data; and all authors have read and approved the final manuscript.

Supported by

the Amrita Vishwa Vidyapeetham SEED grant (K-PHAR-22-662).

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Lekshmi R Nath, PhD, Assistant Professor, Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Ponekkara, Kochi 682041, Kerala, India. lekshmirnath@aims.amrita.edu

Received: March 9, 2022
Peer-review started: March 9, 2022
First decision: April 11, 2022
Revised: April 30, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 28, 2022
Processing time: 197 Days and 22 Hours

Core Tip

Core Tip: Transforming growth factor-beta 1 (TGF-β1) exhibits a progressive elevation throughout hepatic dysfunction starting from hepatitis to hepatocellular carcinoma (HCC) as an inflammatory cytokine, pro-fibrogenic marker, immunosuppressive agent and pro-carcinogenic growth factor. Aberrant TGF-β1 activation in HCC is associated with poor prognosis and survival. TGF-β1 mediated immunosuppression disturbs the anticancer surveillance and the efficacy of the immunotherapeutic agent. This pleiotropic effect of TGF-β1 in the context of HCC makes it ideal as a diagnostic, prognostic, and therapeutic candidate in HCC.